Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
|Poll|April 22, 2016
Right Arm Lesion Found in 37-Year-Old Man
Author(s)Cesar A. Moran, MD
A 37-year old man presents with a bluish lesion in the right arm. After further assessment, a biopsy is performed. What is your diagnosis?
Advertisement
A 37-year old man presents with a bluish lesion in the right arm. According the pathology slide below, what is your diagnosis?
What is your diagnosis?
Advertisement
Related to this article
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.
Catch up on 5 melanoma and skin cancer readouts from ESMO 2026, including NADINA, OptimUM-01, OptimUM-09, C-POST, and KEYNOTE-630.
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5